Company Overview of Prexa Pharmaceuticals, Inc.
Prexa Pharmaceuticals, Inc., a biotechnology company, develops oral small molecule monoamine reuptake inhibitors that act potently at the dopamine transporter. It offers PRX-12251, a dopamine-preferring triple reuptake inhibitor that blocks dopamine, norepinephrine, and serotonin transporters. The company also provides mono and dual reuptake inhibitors. Its products are used to treat central nervous system diseases and disorders, such as attention deficit hyperactivity disorder, depression, and Parkinson’s disease. The company was founded in 2006 and is based in Boston, Massachusetts.
184 High Street
Boston, MA 02110
Founded in 2006
Key Executives for Prexa Pharmaceuticals, Inc.
Similar Private Companies By Industry
|Sophion Bioscience Inc.||United States|
|Cleave Biosciences, Inc.||United States|
|Cantex Pharmaceuticals, Inc.||United States|
|QiG Group, LLC||United States|
|Alios BioPharma, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Prexa Pharmaceuticals, Inc., please visit www.prexainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.